Table 1.

Sample Characteristics

	Total (n=27)		Tried on clozapine (n=13)		Not tried on clozapine (n=14)		Fisher’s exact
Categorical Variable	n	%	n	%	n	%
Gender
Male	22	81.5	12	92	10	71	0.33
Female	5	18.5	1	8	4	29
Race
Caucasian	14	52	6	46	8	57	0.58
Afro-carribean	3	11	2	15	1	7
Aboriginal	4	15	1	8	3	21
Other (eg. Iranian, South East Asian, Mixed race)	6	22	4	31	2	14
Diagnosis
Schizophrenia/Schizoaffective Disorder	21		12		7		0.06
Bipolar Disorder with psychotic symptoms	3		0		3
Psychosis NOS	5		1		4
Level of Psychosis at First Data Entry
0 = residual symptoms	5		2		3		1.00
1= partial symptoms	5		2		3
2 = florid symptoms	17		9		8
Placement Status at First Data Entry
Inpatient	17		8		9		1.00
Outpatient	10		5		5
Continuous/ Ordinal Variable							Wilcoxon Rank-Sum test
Age at First Data Entry
15	2	7.4	2	15	0	0	0.03*
16	11	40.7	7	54	4	29
17	14	51.9	4	31	10	71
Motivation to reduce use at last observation prior “time zero”.
Low	19	73.1	10	83	9	64	0.24
Medium	2	7.7	1	8	1	7
High	5	19.2	1	8	4	26
Severity of THC use at baseline
0 = hardly ever	1		0		1a		0.60
1 = less than once a month	1		1a		0
2 = once a month	3		2		1
3 = 2–3 times per month	4		2		2
6 = > 5 times a week	18		8		10
	Median	IQR	Med	IQR	Med	IQR
Duration of Treatment (months)	14	9–23	21	14–23	11.5	9–16	0.02*

^aThese patients had met criteria for cannabis use disorder prior to first data entry and so were still included in our sample as there was high potential for relapse.

^*indicates p<0.05